Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease [Phase 1]

View source ↗

Summary

A Phase 1 safety and efficacy study of CTX112 in adults with refractory autoimmune diseases, including systemic lupus erythematosus and systemic sclerosis, is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Idiopathic Inflammatory Myopathy
• Lupus Nephritis
• Myositis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CTX112

Snippet

Sponsor: CRISPR Therapeutics | Conditions: SLE (Systemic Lupus), Lupus Erythematosus, Systemic | Phase 1 | Status: RECRUITING